Last reviewed · How we verify
Standard Dose of Unfractionated Heparin
Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.
Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors. Used for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome and myocardial infarction, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Standard Dose of Unfractionated Heparin |
|---|---|
| Sponsor | University of California, Los Angeles |
| Drug class | Anticoagulant |
| Target | Antithrombin III (enhancer); Thrombin (Factor IIa) and Factor Xa (indirect inhibition) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Unfractionated heparin (UFH) is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically increases its ability to inhibit thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the extension of existing thrombi. UFH has a rapid onset of action and is reversible, making it suitable for acute anticoagulation in hospital settings.
Approved indications
- Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Acute coronary syndrome and myocardial infarction
- Atrial fibrillation for stroke prevention
- Prevention of thrombosis during cardiac surgery and percutaneous coronary intervention
- Disseminated intravascular coagulation
Common side effects
- Bleeding (major and minor)
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis (paradoxical, in HIT)
- Osteoporosis (with prolonged use)
- Hyperkalemia
- Injection site reactions
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Dose for Reversal of Heparin After Cardiopulmonary Bypass (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (PHASE1)
- Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: